Givaudan Strikes Deal For Amyris Ingredients, Long-Term Partnership
Executive Summary
The deal has Amyris selling three key cosmetic ingredients to Givaudan and producing more biotech ingredients for the Swiss firm over the long term. “In the future, we will continue to push the boundaries of biotech, creating new sustainable innovations for a better beauty future,” says Givaudan’s Maurizio Volpi, president, Fragrance and Beauty.
You may also be interested in...
Amyris Moving 30 Molecules Through R&D Pipeline, Streamlining Consumer Portfolio
Amyris, Inc. is developing 30 molecules using its bio-fermentation technology, negotiating a bio-manufacturing joint venture that could yield $50m-$100m in proceeds, and simplifying its Consumer portfolio to unlock value. Cost containment and liquidity will continue to be key priorities for the synthetic biotech firm while it targets up to 100% revenue growth in fiscal 2023.
Biotech Amyris Raises Q1 Guidance, Closes On Givaudan Deal
Emeryville, Calif.-based synthetic biotechnology firm Amyris Inc. is raising its first quarter revenue guidance 12% to $56m as its new Brazilian biomanufacturing facility is delivering product at target. The firm also reports it has closed on its $500m deal with Givaudan SA.
Firmenich, IFF Tout Eco-Fragrance Design Tools; Inter Parfums’ Sales Soar In Q4; Fragrance Sales & Sustainability News
Firmenich and International Flavors & Fragrances’ LRM Naturals announce developments to better support customers’ sustainable product development and transparency needs. Givaudan, Symrise and Inter Parfums report strong results in fiscal 2022, fueled by unleashed fragrance demand around the globe.